» Articles » PMID: 26902116

Development of Exosome Surface Display Technology in Living Human Cells

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2016 Feb 24
PMID 26902116
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Surface display technology is an emerging key player in presenting functional proteins for targeted drug delivery and therapy. Although a number of technologies exist, a desirable mammalian surface display system is lacking. Exosomes are extracellular vesicles that facilitate cell-cell communication and can be engineered as nano-shuttles for cell-specific delivery. In this study, we report the development of a novel exosome surface display technology by exploiting mammalian cell secreted nano-vesicles and their trans-membrane protein tetraspanins. By constructing a set of fluorescent reporters for both the inner and outer surface display on exosomes at two selected sites of tetraspanins, we demonstrated the successful exosomal display via gene transfection and monitoring fluorescence in vivo. We subsequently validated our system by demonstrating the expected intracellular partitioning of reporter protein into sub-cellular compartments and secretion of exosomes from human HEK293 cells. Lastly, we established the stable engineered cells to harness the ability of this robust system for continuous production, secretion, and uptake of displayed exosomes with minimal impact on human cell biology. In sum, our work paved the way for potential applications of exosome, including exosome tracking and imaging, targeted drug delivery, as well as exosome-mediated vaccine and therapy.

Citing Articles

Developing anti-TDE vaccine for sensitizing cancer cells to treatment and metastasis control.

Meena S, Kosgei B, Soko G, Tingjun C, Chambuso R, Mwaiselage J NPJ Vaccines. 2025; 10(1):18.

PMID: 39870669 PMC: 11772600. DOI: 10.1038/s41541-024-01035-3.


Efficient Enzymatic Glycan Engineering of Extracellular Vesicles Using Nanomaterial-Interfaced Microfluidics.

Zhou X, Jaiswal M, Shi J, Guo J, Kundu S, Guo Z ACS Appl Mater Interfaces. 2024; 17(1):2689-2700.

PMID: 39698856 PMC: 11832284. DOI: 10.1021/acsami.4c20294.


Engineered extracellular vesicles as nanosponges for lysosomal degradation of PCSK9.

Wang C, Zhou X, Bu T, Liang S, Hao Z, Qu M Mol Ther. 2024; 33(2):471-484.

PMID: 39604267 PMC: 11853006. DOI: 10.1016/j.ymthe.2024.11.034.


CD81-guided heterologous EVs present heterogeneous interactions with breast cancer cells.

Gurrieri E, Carradori G, Roccuzzo M, Pancher M, Peroni D, Belli R J Biomed Sci. 2024; 31(1):92.

PMID: 39402557 PMC: 11475557. DOI: 10.1186/s12929-024-01084-9.


Engineered extracellular vesicles with polypeptide for targeted delivery of doxorubicin against EGFR‑positive tumors.

Yang Y, Wang F, Li Y, Chen R, Wang X, Chen J Oncol Rep. 2024; 52(5).

PMID: 39329273 PMC: 11465103. DOI: 10.3892/or.2024.8813.